The use of the regulatory polypeptide Selank and combined phototherapy to enhance the efficiency of treatment in patients with atopic dermatitis

DOI: https://doi.org/10.29296/25877305-2020-11-06
Download full text PDF
Issue: 
11
Year: 
2020

E. Dontsova, L. Novikova, L. Borzunova, A. Bakhmetyev, N. Voronkova N.N. Burdenko Voronezh
State Medical University

In view of the insufficient efficiency of the currently known procedures to treat patients with atopic dermatitis (AD), there is a need to search for new approaches to solving this problem. Objective: to elaborate a therapeutic approach to treating patients with AD on the basis of combination use along with basic agents, as well as a drug from the group of regulatory peptides (such as Selank) and combined phototherapy (CPT). Subjects and methods. A group of 124 patients (mean age, 23.70±6.06 years) underwent a comparative evaluation of the efficiency of basic drug therapy (BDT) for AD, by additionally using the regulatory polypeptide Selank and CPT (narrowband medium-wave and broadband long-wave radiation (UVB-311 nm/UVA-320-400 nm)), as well as combinations thereof. Results. The combined use of BDT, Selanka, and CPT revealed the potentiation of the clinical effects of the therapeutic procedures used. At 1-year follow-up, the relative risk reduction in disease recurrence was 36% in the Selank + BDT group, 42% in the CPT + BDT group, and 78% in the Selank + CPT + BDT group, as compared to the BDT group. Conclusion. The developed treatment option provides the most effective reduction (78.8%) in the severity of cutaneous manifestations of AD, as shown by the SCORAD index, a 64.7% improvement in quality of life, and a 78% relative risk reduction in disease recurrence, as compared to BDT results.
Keywords: 
dermatology
therapy
atopic dermatitis
Selank
combined phototherapy

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kubanov A.A., Bogdanova E.V. Organizatsija i rezul'taty okazanija meditsinskoj pomoschi po profilju dermatovenerologija v Rossijskoj Federatsii. Itogi 2018 goda. Vestnik dermatologii i venerologii. 2019; 95 (4): 8–23 [Kubanov A.A., Bogdanova E.V. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik dermatologii i venerologii. 2019; 95 (4): 8–23 (in Russ.)]. DOI: 10.25208/0042-4609-2019-95-4-8-23
  2. Psomadakis C.E., Han G. New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis. J Clin Aesthet Dermatol. 2019; 12: 28–34.
  3. Elisjutina O.G., Litovkina A.O., Smol'nikov E.V. i dr. Klinicheskie osobennosti razlichnyh fenotipov atopicheskogo dermatita. Rossijskij allergologicheskij zhurnal. 2019; 16 (4): 30–41 [Elisyutina O.G., Litovkina A.O., Smolnikov E.V. et al. Clinical features of various phenotypes of atopic dermatitis. Russian Journal of Allergy. 2019; 16 (4): 30–41 (in Russ.)]. DOI: 10.36691/RAJ.2020.16.4.004
  4. Shadyzheva L.I. Sovershenstvovanie profilaktiki obostrenij atopicheskogo dermatita s uchetom molekuljarno-geneticheskih i immunologicheskih biomarkerov. Avtoref. dis. ... kand. med. nauk. M., 2018; 25 s. [Shadyzheva L.I. Sovershenstvovanie profilaktiki obostrenii atopicheskogo dermatita s uchetom molekulyarno-geneticheskikh i immunologicheskikh biomarkerov. Avtoref. dis. ... kand. med. nauk. M., 2018; 25 s. (in Russ.)].
  5. Yang G., Seok J.K., Kang H.C. et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020; 21 (8): 2867. DOI:10.3390/ijms21082867
  6. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol. 1980; 92 (1): 44–7. DOI: 10.2340/00015555924447
  7. Korostovtsev D.S., Makarova I.V., Revjakina V.A. i dr. Indeks SCORAD – ob'ektivnyj i standartizovannyj metod otsenki porazhenija kozhi pri atopicheskom dermatite. Allergologija. 2000; 3: 39–43 [Korostovcev D.S., Makarova I.V., Revjakina V.A. et al. Indeks SCORAD – ob»ektivnyi i standartizovannyi metod otsenki porazheniya kozhi pri atopicheskom dermatite. Allergologija. 2000; 3: 39–43 (in Russ.)].
  8. Finlay A.Y. Quality of life assessments in dermatology. Semin Cutan Med Surg. 1998; 17 (4): 291–6. DOI: 10.1016/s1085-5629(98)80026-6
  9. Kochergin N.G. Osnovnye aspekty patogeneza, kliniki i sovremennoj terapii atopicheskogo dermatita. Avtoref. diss. … d-ra med. nauk. M., 2001; 30 s. [Kochergin N.G. Osnovnye aspekty patogeneza, kliniki i sovremennoi terapii atopicheskogo dermatita. Avtoref. diss. … d-ra med. nauk. M., 2001; 30 s. (in Russ.)].
  10. Pirkhammer D., Seeber A., Hönigsmann H. et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment for patients with severe seborrheic dermatitis. Br J Dermatol. 2000; 143: 130–3. DOI: 10.1046/j.1365-2133.2000.03828
  11. Skripkin Ju.K., Dvornikov A.S., Kruglova i dr. Sovremennyj vzgljad na patogeneticheskuju terapiju atopicheskogo dermatita. Vestnik dermatologii i venerologii. 2006; 4: 36–9 [Skripkin Yu.K., Dvornikov A.S., Kruglova L.S. et al. Modern approach to pathogenetic therapy of atopic dermatitis. Vestnik dermatologii i venerologii. 2006; 4: 36–9 (in Russ.)].
  12. Olisova O.Ju., Vladimirov V.V., Murahovskaja E.K. Fototerapija atopicheskogo dermatita UFA-luchami 370 nm. Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2013; 6: 22–7 [Olisova O.J., Vladimirov V.V., Murakhovskaya E.K. UVA 370 nm phototherapy of atopic dermatitis. Russian Journal of Skin and Venereal Diseases. 2013; 6: 22–7 (in Russ.)].
  13. Kosheleva I.V., Hasanova A.R. Sovremennye terapevticheskie podhody k atopicheskomu dermatitu: rol' fototerapii i poisk novyh putej. Lechaschij vrach. 2018; 4: 24–6 [Kosheleva I.V., Khasanova A.R. Contemporary therapeutic approaches to atopic dermatitis: role of phototherapy and searching for new possibilities. Lechashhij vrach. 2018; 4: 24–6 (in Russ.)].
  14. Kruglova L.S. Shirokopolosnaja sredne-dlinnovolnovaja fototerapija v lechenii bol'nyh atopicheskim dermatitom. Vestnik Rossijskogo gosudarstvennogo meditsinskogo universiteta. 2007; 6 (59): 55–62 [Kruglova L.S. Wideband middle/long-wave phototherapy for treatment of atopic dermatitis. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2007; 6 (59): 55–62 (in Russ.)].
  15. Lalajan T., Korzhavina N. Selank v lechenii bolevogo sindroma v pojasnichno-kresttsovom otdele pozvonochnika. Vrach. 2014; 9: 30–4. [Lalayan T., Korzhavina N. The influence of selank on course of pain syndrom in patients with chronic pain syndroms of lumbosacral spine. Vrach. 2014; 9: 30–4 (in Russ.)].
  16. Medvedev V.E., Tereschenko O.N., Kost N.V. i dr. Optimizatsija terapii trevozhnyh rasstrojstv peptidnym preparatom selank. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2015; 115 (6): 33–40 [Medvedev V.E., Tereshchenko O.N., Kost N.V. et al. Optimization of the treatment of anxiety disorders with selank. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2015; 115 (6): 33–40 (in Russ.)]. DOI: 10.17116/jnevro20151156133-40
  17. Verbenko V.A., Shakina T.A. Osobennosti anksioliticheskogo i stressoprotektivnogo dejstvija peptidnogo preparata Selank® pri terapii rasstrojstv adaptatsii i posttravmaticheskogo stressovogo rasstrojstva. Meditsinskij alfavit. 2017; 3 (32); 21–6. [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.)].
  18. Samotrueva M.A., Jasenjavskaja A.L., Bashkina O.A. i dr. Gliproliny kak moduljatory immunoreaktivnosti v uslovijah «sotsial'nogo» stressa. Farmatsija i farmakologija. 2019; 7 (4): 224–30 [Samotrueva M.A., Yasenyavskaya A.L., Bashkina O.A. et al. Glyprolines as modulators of immunoreactivity within conditions of «social» stress. Pharmacy & Pharmacology. 2019; 7 (4): 224–30 (in Russ)]. DOI: 10.19163/2307-9266-2019-7-4-224-230
  19. Jasenjavskaja A.L., Samotrueva M.A., Bashkina O.A. i dr. Nejropeptidnaja reguljatsija immuniteta. Immunologija. 2018; 39 (5–6): 326–36 [Yasenyavskaya A.L., Samotrueva M.A., Bashkina O.A. et al. Neuropeptide regulation of immunity. Immunologija. 2018; 39 (5–6): 326–36 (in Russ.)]. DOI: 10.18821/0206-4952-2018-39-5-6-326-336